Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp55 | Acromegaly and GH | ECE2019

Acromegaly do not increase the risk of vertebral fractures: a retrospective and prospective study on 50 patients

Hochman Clarisse , Plard Charlotte , Le Bras Maelle , Le Goff Benoit , Maugars Yves , Guillot Pascale , Cariou Bertrand , Drui Delphine

Context: Previous studies suggest that patients with acromegaly were at higher risk of vertebral fractures (VFs) despite normal bone mineral density (BMD). However, these patients could have several associated endocrine deficits known to increase the fracture risk, such as hypogonadism. In addition, patients with acromegaly have radiological deformations of the spine, called Erdheim’s syndrome, which can overestimate the radiological VFs.Objective: ...

ea0081oc7.3 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Clinical practice outcomes from 107 patients with Cushing’s syndrome treated with osilodrostat in France

Dormoy Alexandre , Haissaguerre Magalie , Drui Dephine , Demarquet Lea , Do Cao Christine , Guignat Laurence , Vaillant C , Papegaey Anne-Cecile , Raznik Yves , Bras Maelle Le , Salenave S , Raingeard Isabelle , Tauveron I , Christine Vantyghem Marie , Francois M , Delemer B , Luca Florina , Mayer Anne , Petit Jean-Michel , Baudin Eric , Chanson Philippe , Castinetti Frederic , Raverot Gerald , Chabre Olivier , Tabarin Antoine , Young Jacques

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drug’s efficacy and safety in patients with Cushing’s disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushing’s syndrome (CS) in adults....